OncoMatch/Clinical Trials/NCT05900895
Estradiol Plus Olaparib for Breast Cancer (PHOEBE)
Is NCT05900895 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Olaparib and 17b-estradiol for metastatic breast cancer.
Treatment: Olaparib · 17b-estradiol — Determine the safety and recommended Phase II dose of olaparib in combination with 17b-estradiol in post-menopausal patients with advanced ER+/HER2- breast cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 overexpression (ER+)
ER+
Required: HER2 (ERBB2) wild-type (HER2-)
HER2-
Disease stage
Metastatic disease required
Prior therapy
Must have received: endocrine-based therapy — advanced/metastatic
Received ≥1 prior line of endocrine-based therapy in the advanced/metastatic setting
Cannot have received: systemic chemotherapy
Exception: within the last 3 weeks
Any investigational cancer therapy or systemic chemotherapy in the last 3 weeks
Cannot have received: radiation therapy
Exception: within the last 2 weeks
Any radiation therapy in the last 2 weeks
Lab requirements
Kidney function
creatinine clearance > 30 ml/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dartmouth Cancer Center · Lebanon, New Hampshire
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify